 |
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312 773X (Online)
Issue: 2006, Volume 12, book 1
DOI:
Subject Collection: Urology
Page:
Date of close: November 2006
CONTENTS:
THE EFFECT OF ERBISOL ON PRODUCTION OF IL-1B AND NITRIC OXIDE (NO) BY CELLS OF IMMUNE SYSTEM IN PATIENTS WITH CHRONIC
UROGENITAL CHLAMYDIOSIS IN VITRO.
Fesenkova Valentyna
I., Drannik G. N., Driyanska V. E., Kologrimova V. V.
Institute of Urology, AMN of Ukraine, Kyiv, Ukraine
ABSTRACT: Infection caused by Chlamydia trachomatis is
on the special place among sexually transmitted diseases, due to high
incidence of chronic urogenital chlamydiosis (CUGC), social importance
of the problem and difficulties in treatment. In spite of an active use
of new medicaments, the number of CUGC patients continues to grow therefore
the search for new measures of immunocorrection is also in progress.
Aim: to determine in vitro the functional activity of cells of monocyte-and-macrophage
series in CUGC patients by the production of IL-1B and nitric oxide under the action of immunocorrecting medicament Erbisol.
Materials and methods: the cytokine production was determined
through studying the spontaneous and induced synthesis
of IL-1B by cells of CUGC patients in vitro
by means of immunoenzymatic method employing the test system DIACLONE
(France) and immunoenzymatic analyzer STAT-Fax Plus-303 (USA). The content
of stable metabolite NO-ionic nitrite-NO2- in supernatants of cells of
monocyte and macrophage series was determined by means of spectrophotometry
method using the standart Greiss-reagent.
Results: the IL-1B production
by cells of healthy donors was 44.9±1.29 pg/ml, while the meanindex of
spontaneous IL-1B production in CUGC patients
was statistically higher than in healthies – 156.5±6.2 pg/ml. The activation
of immunocompetent cells by mitogen in patients led to statistical reducing
of monokin production and averaged 119.0±5.0 pg/ml (p<0.05). But the
addition of Erbisol to the patient’s immunocompetent cells stipulated
the increase in IL-1B production almost 1,5
times, averaged 211.7±7.2 pg/ml and did not differ from the inducted cytokine
production in healthy donors (p> 0.05). The spontaneous NO secretion
in patients exceeded 2.5 times the NO level in healthy donors, the induction
by Erbisol led to higher elevation of nitric oxide level in patients –
about 3 times as compared with spontaneous production in healthies and
2 times exceeded the NO production induced by mitogen.
Conclusion: the lack of an increase in IL-1B production during activation by mitogens in CUGC patients in vitro, in
contrast to healthies, can be considered as decrease in the reserve potential
of cells of monocyte-macrophage series against the background of their
high activation. Erbisol demonstrates the potential increase in IL-1B and NO production by patient’s cells, that can be considered as the positive
effect for the perspective empoying of the medicament in a situation when
during a long time the immune system cannot ensure the effective resistance
and destroy pathogen-Chlamydia trachomatis.
MYCOPHENOLATE MOFETIL IN TREATMENT OF CHRONIC
GLOMERULONEPHRITIS
Zub Liliya O.
Institute of Nephrology, Kyiv, Ukraine
SUMMARY: This article studies the action of mycophenolate
mofetil (Cell-Cept) on the rates of cell immunity, the level of proteinuria.
There was also determined its safe usage in patients with chronic glomerulonephritis
concomitant by nephrotic syndrome and the preserved renal function. Cell-Cept
was proved to be successfully used in the immunosuppressive therapy of
patients with membranous glomerulonephritis, as it is easily endured by
patients and it has no considerable side effects. No valuable positive
alterations were found in patients with focal segmental glomerulosclerosis
after Cell-Cept administration during 6 months.
< back >
Last edition: November 4, 2006